Optimizing glycemic control and minimizing the risk of hypoglycemia in patients with type 2 diabetes
Stanley S Schwartz
Published: 22 May 2013
In this article the author argues that in type 2 diabetes, an approach that emphasizes diet and exercise and features a treatment regimen tailored to the needs of the individual to reach glycemic targets is warranted in most patients and provides microvascular and cardiovascular benefit, provided that hypoglycemia is avoided.
Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions
James S Kalus
Published: 16 April 2013
Apixaban, dabigatran and rivaroxaban all have advantages over warfarin for stroke prophylaxis in patients with atrial fibrillation. In this article the author discusses the effect of organ dysfunction on drug disposition, drug–drug interaction potential, and other patient-centered factors to consider when selecting the right antithrombotic therapy for the patient.
A capillary in a diseased glomerulus lets protein into the urine. Picture credit: J. Charles Jennette www.unckidneycenter.org
Eva Vivian, Chelsea Mannebach
Published: 27 March 2013
In this article authors review recent studies and evaluate the benefits and risks of combination therapy with an angiotensin converting enzyme (ACE) inhibitor and angiotensin II receptor blocker (ARB), or a direct renin inhibitor (DRI) to attenuate the progression of diabetic nephropathy.
What really does happen to hemodynamic markers when sublingual nitroglycerin is given in the setting of a PDE5 inhibitor?
Dennis Swearingen, Ajay Nehra, Susie Morelos and Craig A Peterson
Published: 26 February 2013
In this study, investigators examined the magnitude and duration of the interactions (when coadministered with glyceryl trinitrate) of the latest phosphodiesterase type-5 inhibitor avanafil on systolic blood pressure and heart rate compared with sildenafil and placebo.
Stem cell research
Emmanuel A Ho, Neal M Davies
Published: 25 February 2013
Unraveling our understanding of cancer stem cells and their role in the development and progression of acute myeloid leukemia could lead to improved outcomes.
Drugs in Context is a gold open-access, international, peer-reviewed journal publishing a wide range of material relevant to pharmacotherapy, quickly.
Call for papers – Drugs in Context welcomes submissions of original research articles, reviews, opinion pieces and letters.